Adalta Ltd. · ASX:1AD
Adalta — AusBiotech Invest and Partnering Conference 2020
15 slides from Adalta's conference presentation, Oct 27, 2020
Slide 1: ASX Announcement: AdAlta to update on Phase I clinical trial during AusBiotech Invest 2020
27 October 2020 ASX Announcement ADALTA TO UPDATE ON PHASE I CLINICAL TRIAL DURING AUSBIOTECH INVEST 2020 CONFERENCE MELBOURNE Australia, 27 October 2020: AdAlta Limited (ASX:1AD), a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging dru
Slide 2: About AdAlta and AD-214 Phase 1 studies
AdAlta is conducting Phase 1 clinical studies for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need. The Company i
Slide 3: i-bodies: next generation protein therapeutics for difficult targets
i-bodies: next generation protein therapeutics for difficult targets AusBiotechInvest October 2020 AdAlta Limited (ASX:1AD) Tim Oldham, CEO and Managing Director t.oldham@adalta.com.au
Slide 4: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 5: A clinical stage drug discovery company advancing rapidly in 2020
A clinical stage drug discovery company advancing rapidly in 2020 4 Grow by creating and advancing i-body-enabled assets $8m • Progress and partner AD-214 • Add 5 internal assets and 3-5 external partnerships • $8.1 million raised in fully subscribed placement and rights issue to accelerate growth t
Slide 6: Opportunities for our partners
Opportunities for our partners Product partners • License to first-in-class anti-fibrotic i-body platform partners • Co-development solutions for challenging targets Financial partners • Buy in to platform potential at single asset price 4
Slide 7: Lead asset AD-214: first-in-class anti-fibrotic
Lead asset AD-214: first-in-class anti-fibrotic CXCR4 receptor is critical player in AD-214 is first in class: the only CXCR4 development of fibrosis in many organs antagonist being developed for fibrosis CXCR4 Potential in multiple fibrotic and cancer indications Normal Diseased Human lung tissue B
Slide 8: Lead indication IPF: $3b market, poor options
Lead indication IPF: $3b market, poor options Idiopathic Pulmonary Fibrosis (IPF) is irreversible, unpredictable, incurable >300,000 people living with IPF 40,000 people die from IPF every year 3.8 years median survival after diagnosis Current treatments come with safety, efficacy limitations Burden
Slide 9: Current Phase I clinical trial update
Antje Prasse1, Danny Jonigk2, Tobias Welte1, Benedikt Jäger1, Frank Bengel3, Thorsten Derlin3 Current Phase I clinical trial update 1Pneumology, Hannover Medical School; Fraunhofer ITEM, DZL BREATH 2Pathology, Hannover Medical School and 3Nuclear Medicine, Hannover Medical School, Hannover, DE, Back
Slide 10: External pipeline: multi-national GE Healthcare
External pipeline: multi-national GE Healthcare i-body Target: platform granzyme B October ‘20 status • Panel of i-bodies identified • Lead optimization underway (6 mo) • A$1.15 million milestones and research fees earned to date Discovery Development Further milestones and royalties to be earned on
Slide 11: Key execution milestones
Key execution milestones Ph I part A Safety, PK, RO FDA pre-IND Ph I part A top line 1st PET images Ph I part C in NHP advice safety update safety in patients commences AD-214 Efficacy in BLM Ph I part A PET tracer Ph I part B mouse commenced pre-clinical commences Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 Oct ‘
Slide 12: Industry experienced leadership and advisors
Industry experienced leadership and advisors Board Scientific Advisory Board Dr Paul MacLeman Tim Oldham, PhD Brian Richardson Chair CEO & Managing Director Drug discovery and development expert Liddy McCall Dr Robert Peach Steve Felstead (alt: Dr James Williams) Independent Director Clinical develo
Slide 13: Financial position
Financial position Key financial details (23 Oct) Major shareholders (23 Oct) % ASX code 1AD Yuuwa Capital LP 22.0 Market capitalisation A$34.32m Platinum Asset Management 11.6 Meurs Holdings Pty Ltd 7.3 Share price (12 month range) A$0.14 ($0.04-0.18) CS Third Nominees Pty Ltd 3.1 Ordinary Shares (
Slide 14: AdAlta (ASX:1AD) Investment proposition
Molecular Imaging with CXCR4-Gallium-68-Pentixa correlates with GAP Index and Treatment Effects i AdAlta (ASX:1AD) Investment proposition Antje Prasse1, Danny Jonigk2, Tobias Welte1, Benedikt Jäger1, Frank B 1Pneumology, Hannover Medical School; Fraunhofer ITEM, DZL BREAT 2Pathology, Hannover Medica
Slide 15: Contacts for more information
Contacts for more information: Tim Oldham, CEO and Managing Director t.oldham@adalta.com.au www.adalta.com.au
Adalta — AusBiotech Invest and Partnering Conference 2020 on 6ix